Estrategias para mejorar el acceso a medicamentos en el Perú

Ubilluz, Oscar Ugarte

doi:10.15381/anales.v80i1.15878

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is an increased need to develop DUR in Peru due to the increased demand for medications ( UgarteUbilluz, 2019 ). Currently, there is limited and incomplete information on drug use due to various factors, such as inadequate drug information, HCP with basic training on drugs, prescribing and dispensing activities influenced by socio-cultural patient demands and drug promotion, and the weakness of Peruvian drug policies ( Paredes et al, 1996 ; Maldonado et al, 2002 ; Bustamante Robles et al, 2012 ; Florián-Castro, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Drug utilization research in Peru: Is real-world data available?

et al. 2023

View full text Add to dashboard Cite

Background: Drug utilization research (DUR) is used to provide evidence-based data to inform policies and make decisions. The aim of this study was to map and describe available data sources for drug utilization research in Peru.Methods: We performed a search of data sources providing information on medication use on the website of governmental organizations. We also conducted a literature review using PubMed, LILACs, and BVS. Independently, researchers screened eligible data sources. Data characterization included accessibility, coverage data provider, type of data sources, and setting. We performed a descriptive analysis.Results: We identified seven data sources, CENAFyT, ICI, IDI (SISMED), and ENSUSALUD from MINSA, and CRI-ESSALUD, SGSS/ESSI, and ENSSA from ESSALUD. These presented information on adverse drug reactions (n = 2), drug consumption, and distribution (n = 2), prescription and drug dispensing (n = 1), and surveys addressed to medication users (n = 2). ENSUSALUD was the only data source publicly available. VIGIFLOW and ENSUSALUD have a national granularity from the public and private sectors. The setting of the data sources was both hospital and ambulatory care. Two data sources have individual-level data on adverse drug reactions and one on prescriptions. Four studies on drug utilization research in Peru were derived from ENSUSALUD.Conclusion: In Peru, few data sources are available for drug utilization research. There is an increased need to monitor medications for decision-making purposes. Local and international initiatives and partnerships of the government with academic institutions and the private sector might be a good strategy to increase the transparency of health data and for supporting decision-making using drug utilization research.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug utilization research in Peru: Is real-world data available?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…These results are a cause for concern when the public market for medicines represents 71% of the national market and where increasing access to generic medicines has been proposed as a strategy to improve access to medicines in Peru. ( 36 ) However, in spite of the possible mistrust, the annual evolution of generic prescription drug sales has demonstrated a progressive increase globally since 2010, and the strategies for their acceptance have been successful. ( 37 )…”

Section: Discussionmentioning

confidence: 99%

“…( 34 ) Some strategies for the first point have been suggested that include the programming and acquisition of strategic drugs in the Pan American Health Organization (PAHO) according to the prioritized population. ( 36 ) Likewise, strategies for financing according to programming, and coordination with regional governments and health institutions to ensure distribution and application throughout the sector. ( 36 ) Finally, strengthen execution monitoring mechanisms throughout the sector.…”

Section: Discussionmentioning

confidence: 99%

“…( 36 ) Likewise, strategies for financing according to programming, and coordination with regional governments and health institutions to ensure distribution and application throughout the sector. ( 36 ) Finally, strengthen execution monitoring mechanisms throughout the sector. ( 36 ) Regarding improving confidence in generic drugs, PAHO proposes to develop a comprehensive strategy that includes appropriate regulation; promotion of the marketing of generic drug lists of essential drugs, and promotion of extended use of the international common denomination.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Self-Medication Practices, Use of Brand-Name, and Over-the-Counter Medicines by Peruvian Older Adults

et al. 2023

View full text Add to dashboard Cite

Background Older adults are a particularly vulnerable group to drug use and self-medication. The aim of the study was to evaluate self-medication as a factor associated with the purchase of brand-name and over-the-counter (OTC) drugs in older adults in Peru. Methods A secondary analysis was performed using an analytical cross-sectional design of data from a nationally representative survey from 2014 to 2016. The exposure variable was self-medication, defined as the purchase of medicines without a prescription. The dependent variables were purchases of brand-name and OTC drugs, both as a dichotomous response (yes/no). Information of sociodemographic variables, health insurance, and the types of drugs purchased by the participants was collected. Crude prevalence ratios (PR) were calculated and adjusted using generalized linear models of the Poisson family, considering the complex sample of the survey. Results In this study, 1,115 respondents were evaluated, with a mean age of 63.8 years and a male proportion of 48.2%. The prevalence of self-medication was 66.6%, while the proportions of purchases of brand-name and OTC drugs were 62.4% and 23.6%, respectively. The adjusted Poisson regression analysis revealed an association between self-medication and the purchase of brand-name drugs (adjusted PR [aPR]=1.09; 95% confidence interval [CI]: 1.01–1.19). Likewise, self-medication was associated with the purchase of OTC medications (aPR=1.97; 95%CI: 1.55–2.51). Conclusions This study evidenced a high prevalence of self-medication in Peruvian older adults. Two-thirds of the surveyed people bought brand-name drugs, whereas one-quarter bought OTC drugs. Self-medication was associated with a greater likelihood of buying brand-name and OTC drugs.

show abstract

“…The results of our study should be interpreted carefully because it represents to a special cohort without the barriers of access to drugs that is common in the Peruvian public system [ 18 ]. We observed some differences in 5-year survival rate in comparison to data of CONCORD-3 programme evaluating data from the Metropolitan Lima Cancer Registry.…”

Section: Discussionmentioning

confidence: 99%

Life expectancy and cancer survival in Oncosalud: outcomes over a 15-year period in a Peruvian private institution

Colonio¹,

Lecman²,

Pinto³

et al. 2021

ecancer

View full text Add to dashboard Cite

Background: There is a large gap in the data on cancer outcomes in Latin America, making it difficult to establish adequate cancer control policies in the region. The aim of our study was to describe the survival, life expectancy estimates and life expectancy changes over time for a large cohort of Peruvian patients insured with Oncosalud, a private healthcare system. Patients and methods:We evaluated a retrospective cohort of patients diagnosed between 2000 and 2015 in Oncosalud (Lima-Peru). Cases included colon, rectum, stomach, bladder, breast, prostate and non-melanoma skin cancers. Survival was evaluated with the Kaplan-Meier methodology. The standard period life table was used to estimate the excess mortality risks of patients in our cohort compared to the population covered by the Peruvian Superintendence of Banks, Insurance Companies and Pension Funds (SBS). The years of life lost was estimated based on SBS population, matching patients by age and sex.Results: A large cohort of 7,687 Peruvian cancer patients managed in a 15-year period was eligible. If patients survive 5 years after a cancer diagnosis, life expectancy tends to be close to that of a population without cancer. The number of years of life lost at diagnosis was higher at the youngest ages, steadily decreasing thereafter. During the first years after cancer diagnosis, young patients face a much higher loss in life expectancy than older ones. Patients suffering from colon, rectum, stomach and bladder cancer are the most affected by the years of life lost. Conclusion:In cancer patients surviving ≥ 5 years, life expectancy becomes similar to that observed in a population with similar socioeconomic characteristics. The estimated survival rate in our cohort is higher than that reported by public cancer registries in Peru. This could be explained by the different socio-economic background and access to specialised cancer care.

show abstract

Estrategias para mejorar el acceso a medicamentos en el Perú

Cited by 7 publications

References 0 publications

Drug utilization research in Peru: Is real-world data available?

Drug utilization research in Peru: Is real-world data available?

Self-Medication Practices, Use of Brand-Name, and Over-the-Counter Medicines by Peruvian Older Adults

Life expectancy and cancer survival in Oncosalud: outcomes over a 15-year period in a Peruvian private institution

Contact Info

Product

Resources

About